Drug Trial Radar · NCT03756103
Safety and Efficacy of SPH3127 on Treating Mild-moderate Essential Hypertension Patients
Last checked: Nov 19, 2026Latest source record: Nov 15, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
120
Actual
Start
Jan 11, 2019
Primary completion
Jun 30, 2020
Study completion Jun 30, 2020
Sponsor
- Lead sponsor
- Shanghai Pharmaceuticals Holding Co., LtdIndustry
- Sponsor type
- Industry
- Collaborators
- R&G Pharma Studies Co.,Ltd.
- First posted
- Nov 28, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
SPH3127 tablet is a of renin inhibitor. It is expected to be a new drug for essential hypertension. This is a phase IIa trial which designed to evaluate its efficacy and safety on treating mild-moderate essential hypertension patients.
Conditions
- Hypertension,Essential
Interventions
SPH3127 tablet Dose 1Drug
Oral SPH3127 tablet, a kind of renion inhibitor, 50 mg, once daily for 8 weeks.
SPH3127 tablet Dose 2Drug
Oral SPH3127 tablet, a kind of renion inhibitor, 100 mg, once daily for 8 weeks.
SPH3127 tablet Dose 3Drug
Oral SPH3127 tablet, a kind of renion inhibitor, 200 mg, once daily for 8 weeks.
SPH3127 tablet PlaceboDrug
Oral SPH3127 tablet placebo, once daily for 8 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes From Baseline in Seated Systolic Blood Pressure (SBP) and Seated Diastolic Blood Pressure (DBP) After 8 Weeks of Treatment.Time frame: Baseline to 54-58 days
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Beijing Anzhen Hospital, Capital Medical University
Beijing, China
Beijing Hospital
Beijing, China
The Second Xiangya Hospital of Central South University
Changsha, China
Xiangya Hospital Central South University
Changsha, China
West China Hospital of Sichuan University
Chengdu, China
Second People's Hospital of Guangdong Province
Guangdong, China
Inner Mongolia Medical University Affiliated Hospital
Hohhot, China
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, China
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China
Xuzhou Central Hospital
Xuzhou, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.